Vice President and
Region Head
Regional Sales Lead,
Sales and Marketing
Regional Sales Manager,
Sales and Marketing
Associate VP, Business Development,
Sales and Marketing
Associate Director, Marketing
CPHI Japan is the premier event for the pharmaceutical industry in Japan, providing a platform for international companies to connect and do business with key players in the Japanese market. In its 20th anniversary, the event is expected to attract over 200 exhibitors from across the entire pharmaceutical supply chain, showcasing the latest products, solutions, and innovations in the industry.
Attendees can expect to discover the latest products and services from ingredients, contract services, and biopharma to technology, packaging, and machinery. They will also have the opportunity to meet and network with industry leaders, search for potential partners, and arrange meetings with potential partners online through the event's chat service.
Whether you are a large multinational corporation or a small start-up, CPHI Japan provides the perfect platform to expand your horizons in the Japanese pharmaceutical market. Join us at the event and take advantage of the unique opportunities to connect and grow your business.
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。